Related Experiment Video
Updated: May 24, 2026

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics
Published on: April 9, 2017
γ-Glutamylamines and neurodegenerative diseases
Thomas M Jeitner1, Kevin Battaile, Arthur J L Cooper
1Neurosciences, Biomedical Research Core, Winthrop University Hospital, 222 Station Plaza North, Mineola, USA. tjeitner@winthrop.org
Abstract:
Transglutaminases catalyze the formation of γ-glutamylamines utilizing glutamyl residues and amine-bearing compounds such as lysyl residues and polyamines. These γ-glutamylamines can be released from proteins by proteases in an intact form. The free γ-glutamylamines can be catabolized to 5-oxo-L-proline and the free amine by γ-glutamylamine cyclotransferase. Free γ-glutamylamines, however, accumulate in the CSF and affected areas of Huntington Disease brain. This observation suggests transglutaminase-derived γ-glutamylamines may play a more significant role in neurodegeneration than previously thought. The following monograph reviews the metabolism of γ-glutamylamines and examines the possibility that these species contribute to neurodegeneration.
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Alzheimer's Disease: Treatment
Hepatic Encephalopathy
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer Disease ll: Pathophysiology

